Annual Accounts Payable
$6.57 M
+$3.08 M+88.30%
30 September 2023
Summary:
Outlook Therapeutics annual accounts payable is currently $6.57 million, with the most recent change of +$3.08 million (+88.30%) on 30 September 2023. During the last 3 years, it has risen by +$4.38 million (+199.34%). OTLK annual accounts payable is now -43.14% below its all-time high of $11.56 million, reached on 30 September 2014.OTLK Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$5.55 M
+$1.19 M+27.26%
30 June 2024
Summary:
Outlook Therapeutics quarterly accounts payable is currently $5.55 million, with the most recent change of +$1.19 million (+27.26%) on 30 June 2024. Over the past year, it has dropped by -$1.02 million (-15.54%). OTLK quarterly accounts payable is now -61.48% below its all-time high of $14.42 million, reached on 31 March 2016.OTLK Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OTLK Accounts Payable Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | - | -15.5% |
3 y3 years | +199.3% | +152.8% |
5 y5 years | +188.6% | +143.8% |
OTLK Accounts Payable High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | at high | +199.3% | -15.5% | +152.8% |
5 y | 5 years | at high | +199.3% | -15.5% | +152.8% |
alltime | all time | -43.1% | +199.3% | -61.5% | +152.8% |
Outlook Therapeutics Accounts Payable History
Date | Annual | Quarterly |
---|---|---|
June 2024 | - | $5.55 M(+27.3%) |
Mar 2024 | - | $4.36 M(+25.4%) |
Dec 2023 | - | $3.48 M(-47.1%) |
Sept 2023 | $6.57 M(+88.3%) | $6.57 M(+30.0%) |
June 2023 | - | $5.06 M(+39.7%) |
Mar 2023 | - | $3.62 M(-13.2%) |
Dec 2022 | - | $4.17 M(+19.4%) |
Sept 2022 | $3.49 M(+59.0%) | $3.49 M(+40.7%) |
June 2022 | - | $2.48 M(-40.4%) |
Mar 2022 | - | $4.16 M(+63.4%) |
Dec 2021 | - | $2.55 M(+15.9%) |
Sept 2021 | $2.20 M(-8.3%) | $2.20 M(-17.8%) |
June 2021 | - | $2.67 M(-57.8%) |
Mar 2021 | - | $6.33 M(+89.9%) |
Dec 2020 | - | $3.33 M(+39.2%) |
Sept 2020 | $2.39 M | $2.39 M(-52.2%) |
June 2020 | - | $5.01 M(+51.5%) |
Mar 2020 | - | $3.31 M(+28.8%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2019 | - | $2.57 M(+12.7%) |
Sept 2019 | $2.28 M(-36.9%) | $2.28 M(-23.8%) |
June 2019 | - | $2.99 M(-41.6%) |
Mar 2019 | - | $5.11 M(+8.9%) |
Dec 2018 | - | $4.70 M(+30.1%) |
Sept 2018 | $3.61 M(-67.0%) | $3.61 M(+7.7%) |
June 2018 | - | $3.35 M(-7.1%) |
Mar 2018 | - | $3.61 M(-0.6%) |
Dec 2017 | - | $3.63 M(-66.9%) |
Sept 2017 | $10.95 M(+116.0%) | $10.95 M(-7.1%) |
June 2017 | - | $11.79 M(-3.0%) |
Mar 2017 | - | $12.15 M(+10.0%) |
Dec 2016 | - | $11.05 M(+117.9%) |
Sept 2016 | $5.07 M(-56.1%) | $5.07 M(+11.8%) |
June 2016 | - | $4.53 M(-68.5%) |
Mar 2016 | - | $14.42 M(+24.1%) |
Dec 2015 | - | $11.62 M(+0.5%) |
Sept 2015 | $11.56 M(0.0%) | $11.56 M |
Sept 2014 | $11.56 M | - |
FAQ
- What is Outlook Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly accounts payable year-on-year change?
What is Outlook Therapeutics annual accounts payable?
The current annual accounts payable of OTLK is $6.57 M
What is the all time high annual accounts payable for Outlook Therapeutics?
Outlook Therapeutics all-time high annual accounts payable is $11.56 M
What is Outlook Therapeutics quarterly accounts payable?
The current quarterly accounts payable of OTLK is $5.55 M
What is the all time high quarterly accounts payable for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly accounts payable is $14.42 M
What is Outlook Therapeutics quarterly accounts payable year-on-year change?
Over the past year, OTLK quarterly accounts payable has changed by -$1.02 M (-15.54%)